MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Lung Cancer Treatments and Mutations
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,464 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,464 works in the cohort · of 4,299,418page 4 of 50

Labels cover 16 of 2,464 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,464 of 2,464 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affunlabeled
Afatinib restrains K-RAS–driven lung tumorigenesis
Herwig P. Moll, Klemens Pranz, Mónica Musteanu, Beatrice Grabner, Natascha Hruschka, Julian Mohrherr +19 more
2018· article· en· Science Translational Medicine· Medicine
distilled prediction:candidate · insufficient_payloadconsensus · none
126
citations
affno abstractgemma · no categorygpt · no categorymodels agree
Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer
Giorgio V. Scagliotti, Silvia Novello, Joan H. Schiller, Vera Hirsh, Lecia V. Sequist, Jean‐Charles Soria +4 more
2012· article· en· Clinical Lung Cancer· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
126
citations
aboutno affunlabeled
A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1<sup>st</sup> line or 2<sup>nd</sup> line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial
Frances A. Shepherd, J. Pereira, Tudor–Eliade Ciuleanu, E. H. Tan, V. Hirsh, S. Thongprasert +4 more
2004· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · metaresearch+metaepi_narrowconsensus · none
119
citations
← previousnext →

How this was built: Screen · Findings · About